Skip to search formSkip to main contentSkip to account menu

Erlotinib Hydrochloride

Known as: Erlotinib HCl, Erlotinib Hydrochloride [Chemical/Ingredient], Hydrochloride, Erlotinib 
The hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds… 
National Institutes of Health

Related topics

Related topics

20 relations

Broader (3)

Antineoplastic AgentsProtein Kinase Inhibitorserlotinib

Narrower (3)

CP 358774OSI-774Tarceva
EGFR protein, humanGemcitabine-Erlotinib RegimenIn BloodInhibition of Cell Proliferation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
IMPORTANCE Randomized clinical trials demonstrate no benefit for epidermal growth factor receptor (EGFR) tyrosine kinase… 
2013
2013
Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer
Erlotinib is approved for the treatment of non–small cell lung and pancreatic cancers, and is metabolized by CYP3A4. Inducers and… 
2012
2012
Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.
BACKGROUND To increase knowledge about lung tumor tissue levels of erlotinib and its primary active metabolite, and about… 
2010
2010
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
BACKGROUND Erlotinib and pemetrexed are approved single agents for second-line treatment of non-small-cell lung cancer (NSCLC… 
2010
2010
Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia.
Case 1 A 62-year-old nonsmoker man who suffered from a weight loss of 2 kg in 2 months was found to have lung adenocarcinoma with… 
2009
2009
Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514.
8098 Background: BMS-690514 is an oral selective inhibitor of EGFR, HER2, and VEGFR1-3. Previous results from the phase I portion… 
Highly Cited
2006
Highly Cited
2006
A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride…
7062 Background: Bevacizumab is a recombinant, humanized anti-VEGF MAb. Erlotinib is a potent, reversible, highly selective and… 
2005
2005
How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care.
Cisplatin (Platinol; Bristol-Myers Squibb, Princeton, NJ, http://www.bms.com) and carboplatin (Paraplatin; Bristol-Myers Squibb… 
2004
2004
Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer.
2000 Background VEGF and HER1/EGFR play a pivotal role in many types of cancer. Bevacizumab (Avastin) is a recombinant, humanized… 
2002
2002
Erlotinib hydrochloride: Oncolytic EGF receptor inhibitor
The epidermal growth factor receptor (EGFR) is a type 1 receptor tyrosine kinase that is involved in the modulation of cellular… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)